Clearmind Submits Addiction Treatment Proposal to U.S. HHS RFI — Clearmind Medicine Inc.

Event summary

Clearmind Medicine submitted a response to the U.S. HHS RFI on addiction treatment innovations under the Great American Recovery Initiative.
The company proposed its MEAI-based candidate CMND-100 as a non-hallucinogenic neuroplastogen for treating alcohol use disorder (AUD).
Clearmind highlighted AUD's prevalence in 10% of the U.S. population, with only 10% receiving treatment.
The submission emphasizes scalable, at-home solutions with low abuse potential and engagement of neural pathways like 5-HT1A.

The big picture

Clearmind's submission aligns with the U.S. Administration's push for innovative, non-opioid solutions to address the addiction crisis. The focus on neuroplastogens represents a strategic shift towards treatments that offer neuroplasticity without hallucinogenic effects, potentially transforming addiction treatment paradigms. The Great American Recovery Initiative underscores the government's commitment to leveraging existing resources to enhance prevention, treatment, and recovery efforts.

What we're watching

Regulatory Approval: Whether CMND-100 can secure FDA approval and gain traction as a scalable, at-home treatment for AUD.
Market Adoption: The pace at which neuroplastogen-based therapies integrate into broader recovery strategies across underserved settings.
Competitive Positioning: How Clearmind differentiates itself in the addiction treatment space with non-hallucinogenic solutions.